Page 158 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 158
226. Schapira MM, Lawrence WF, Katz DA, et 237. Andersson SO, Andren O, Lyth J, et al.
al. Effect of treatment on quality of life Managing localized prostate cancer by
among men with clinically localized prostate radical prostatectomy or watchful waiting:
cancer. Med Care 2001;39:243-253. Cost analysis of a randomized trial (SPCG-
4). Scand J Urol Nephrol 2011;45:177-183.
227. Lubeck DP, Litwin MS, Henning JM, et al.
Changes in health-related quality of life in 238. Ollendorf DA, Hayes JH, McMahon PM, et
the first year after treatment for prostate al. Management options for low-risk
cancer: results from CaPSURE. Urology. prostate cancer. 2009. Insitute for Clinical
1999;53:180-186. and Economic Review. Ref Type: Report
228. Bacon CG, Giovannucci E, Testa M, et al. 239. Ollendorf DA, Hayes JH, McMahon PM, et
The impact of cancer treatment on quality of al. Active surveillance & radical
life outcomes for patients with localized prostatectomy for the management of low-
prostate cancer. J Urol 2001;166:1804-1810. risk, clinically-localized prostate cancer.
January 11, 2009. Institute for Clinical and
229. Litwin MS, Lubeck DP, Spitalny GM, et al. Economic Review. Ref Type: Report
Mental health in men treated for early stage
prostate carcinoma: a posttreatment, 240. Hayes JH, Ollendorf DA, Pearson SD, et al.
longitudinal quality of life analysis from the Active surveillance compared with initial
Cancer of the Prostate Strategic Urologic treatment for men with low-risk prostate
Research Endeavor. Cancer 2002;95:54-60. cancer: a decision analysis. JAMA
2010;304:2373-2380.
230. Schymura MJ, Kahn AR, German RR, et al.
Factors associated with initial treatment and 241. Corcoran AT, Peele PB, Benoit RM. Cost
survival for clinically localized prostate comparison between watchful waiting with
cancer: results from the CDC-NPCR active surveillance and active treatment of
Patterns of Care Study (PoC1). BMC Cancer clinically localized prostate cancer. Urology
2010;10:152. 2010;76:703-707.
231. Berge V, Thompson T, Blackman D. 242. Eldefrawy A, Katkoori D, Abramowitz M,
Additional surgical intervention after radical et al. Active surveillance vs. treatment for
prostatectomy, radiation therapy, androgen- low-risk prostate cancer: A cost comparison.
deprivation therapy, or watchful waiting. Urol Oncol 2011.
Eur Urol 2007;52:1036-1043.
243. Robins J, Orellana L, Rotnitzky A.
232. Rice KR, Colombo ML, Wingate J, et al. Estimation and extrapolation of optimal
Low risk prostate cancer in men >/= 70 treatment and testing strategies. Stat Med
years old: To treat or not to treat. Urol Oncol 2008;27:4678-4721.
2011.
244. Hernan MA, Lanoy E, Costagliola D, et al.
233. Rothman KJ. No adjustments are needed for Comparison of dynamic treatment regimes
multiple comparisons. Epidemiology via inverse probability weighting. Basic Clin
1990;1:43-46. Pharmacol Toxicol 2006;98:237-242.
234. Greenland S, Robins JM. Empirical-Bayes 245. Srigley JR, Amin MB, Bostwick DG, et al.
adjustments for multiple comparisons are Updated protocol for the examination of
sometimes useful. Epidemiology specimens from patients with carcinomas of
1991;2:244-251. the prostate gland: a basis for checklists.
Cancer Committee. Arch Pathol Lab Med
235. Penson DF, Schonfeld WH, Flanders SC, et 2000;124:1034-1039.
al. Relationship of first-year costs of treating
localized prostate cancer to initial choice of 246. Thompson IM, Canby-Hagino E, Lucia MS.
therapy and stage at diagnosis: results from Stage migration and grade inflation in
the CAPSURE database. Urology prostate cancer: Will Rogers meets Garrison
2001;57:499-503. Keillor. J Natl Cancer Inst 2005;97:1236-
1237.
236. Wilson LS, Tesoro R, Elkin EP, et al.
Cumulative cost pattern comparison of
prostate cancer treatments. Cancer
2007;109:518-527.
104
